NEW STUDY

26.2% of low & medium risk nodules moved to high-risk within just 12 months

whitebook

Download the Clinical Perspective

In this Clinical Perspective

Results from a retrospective study following 6,380 patients with incidental pulmonary nodules.

Evidence that questions select Fleischner Risk recommendations.

The clinical and financial impact of failing to follow patients with low and moderate-risk nodules.

Scott Skibo headshot

Dr. Scott Skibo

MD, FCCP, Chief Medical Officer, Eon

Connect on LinkedIn

About the Author:

Dr. Skibo completed his pulmonary and critical care fellowship at Yale University in 2004. In 2012 at Gundersen Health, Western Campus for the University of Wisconsin School of Medicine and Public Health, he co-implemented one of the first system-wide incidental pulmonary nodule programs in the country. From there, he moved to Haywood Regional Medical Center in Clyde, NC, where he built and led a lung cancer program that gained national recognition as a Lung Cancer Center of Excellence. Dr. Skibo and Haywood were an early adopter of Eon solutions for lung cancer screening and incidental pulmonary nodule management, and understand the value Eon brings to an early detection lung cancer program. The success of Eon at Haywood led parent company LifePoint Health to expand Eon to all 88 hospitals. Dr. Skibo has been the Chief Medical Officer at Eon for nearly 5 years.

About Eon:

Eon is the leading AI-powered longitudinal care management platform that transforms incidental findings management from a missed opportunity into a strategic growth driver. Trusted by 70 health systems and in use at more than 1,000 facilities, Eon enables health systems to improve early cancer detection and time to treatment, achieve meaningful stage shift, and drive substantial revenue growth by surfacing patients in need of diagnosis, treatment, and curative intent therapies and by continuously monitoring for as long as surveillance is necessary. With over 500 million patient records analyzed, Eon has extensive experience and proven clinical impact and financial outcomes for health systems.

© 2026 Eon. All rights reserved.